Informations générales (source: ClinicalTrials.gov)
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients (LUNG-RESIST)
Interventional
N/A
University Hospital, Toulouse (Voir sur ClinicalTrials)
mars 2021
décembre 2028
06 juillet 2024
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are effective
therapies for advanced lung cancer patients bearing EGFR-activating mutations, but are
not curative due to the invariable apparition of resistances. The investigator team have
identified a new phenotype related to drug tolerance after EGFR-TKI treatment that shares
several characteristics of a known process of Therapy-Induced Senescence (TIS), which
could be a major event of drug tolerance in patients. Using cutting-edge technologies,
patient-derived xenografts (PDX) and circulating tumor cells (CTC), the investigator team
will perform an exhaustive characterization of the phenotypic and molecular changes
associated with this drug-tolerant state in patients. Their results should lead to new
therapeutic approaches to eliminate the reservoir of drug-tolerant cells and to prevent
emergence of resistance mutations responsible for the relapse of patients.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Toulouse University Hospital - 31300 - Toulouse - Occitanie - France | Sandra BERNARD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient with non operable and / or metastatic non-small cell lung cancer documented
histologically.
- Pathological diagnosis of NSCLC carrying an EGFR activating mutation associated with
sensitivity to the tyrosine kinase inhibitors (TKI) (exons 18, 19 and 21).
- Sufficient tissue sample quantity and quality for translational research
- Naïve TKI-treated EGFR patient who can receive first-line treatment with Osimertinib
or second-line after chemotherapy
- Patient with non operable and / or metastatic non-small cell lung cancer documented
histologically.
- Pathological diagnosis of NSCLC carrying an EGFR activating mutation associated with
sensitivity to the tyrosine kinase inhibitors (TKI) (exons 18, 19 and 21).
- Sufficient tissue sample quantity and quality for translational research
- Naïve TKI-treated EGFR patient who can receive first-line treatment with Osimertinib
or second-line after chemotherapy
- Any patient with an exon 20 EGFR mutation.
- Any disease or pathology that recommend not to perform blood samples collection
- Any psychological, family, geographical or social condition that could potentially,
according to the investigator's judgment, prevent the collection of informed consent
or interfere with compliance with the study protocol
- Patient with a resistance mutation of EGFR
- Patient under State Medical Assistance
- Patient deprived of liberty on administrative or judicial decision, or patient under
guardianship, curatorship or safeguard of justice